Ready to start planning your care? Call us at 800-525-2225 to make an appointment.





About Us Sloan Kettering Institute The Gabriela Chiosis Lab

Research

Liza Shrestha, PhD

Education & Training Research Fellow



Email


shresthl@mskcc.org

Liza Shrestha 1/5

Start Year

2014

I received my PhD in Medicinal Chemistry and Molecular Pharmacology from Purdue University. My dissertation involved substrate-based synthesis of isoprenylcysteine carboxyl methyltransferase (lcmt) inhibitors to combat K-Ras mediated pancreatic cancer as well as several other neoplasias. During my graduate career, I successfully generated an extensive library of bioactive small molecules, which have strengthened the SAR and resulted in the discovery of low nanomolar inhibitors. These inhibitors exhibit promising antiproliferative effects on pancreatic cancer cells. As a part of my research, I also synthesized benzophenone based photoaffinity probes for effective identification of lcmt active site residues.



At present, I am a postdoctoral research fellow in the Chiosis group. My research involves the rational development of small molecule anticancer therapeutics that target heat shock protein 70 (HSP70). I am involved in the optimization of the potency profile as well as the physicochemical properties of Hsp70 inhibitors. In parallel with our rational strategy to generate allosteric Hsp70 inhibitors, we perform preclinical testing in several xenograft mice models with the ultimate goal of designing a small molecule that can

Liza Shrestha 2/5

transition into the clinic. My training in the Chiosis lab has allowed me to acquire skill sets required to understand and appreciate the various phases of translational research starting from chemical design to pharmacological assays to preclinical *in vivo* studies.

Patents

Chiosis, Gabriela; Taldone, Tony; Shrestha, Liza; Koren, John; Gomes-Dagama, Erica. Rational synergistic combination therapy for the treatment of cancer using inhibitors of chaperone proteins such as HSP90 inhibitors. WO 2017062520 (A1), Apr 13, 2017.

Chiosis, Gabriela; Taldone, Tony; Patel, Hardik J.; Patel, Maulik; Patel, Pallav; Ochiana, Stephan; Shrestha, Liza. Preparation of (hetero)arylthiopyrimidine compounds as Hsp70 modulators. WO 2015175707 (A1), Nov 19, 2015.

Gibbs, Richard, A.; Bergman, Joel, A.; Hahne, Kalub; Hrycyna, Christine, A.; Shrestha, Liza; Lill, Markus, A.; Wilson, Gregory; Majmudar, Jaimeen. 2013. Methods for use of sesquiterpene heterocyclic compounds in treating neoplasia and cancer. WO2013016531 (A2), Jan 31, 2013.

Liza Shrestha 3/5

Publications

Shrestha, L.; Bolaender, A; Patel, H. J.; Taldone, T., HSP Drug Discovery and Development: Targeting Heat Shock Proteins in Disease. *Curr. Top. Med. Chem.* 2016, 16(25), 2753-64.

Shrestha, L.; Young, J. C., Function and Chemotypes of Human Hsp70 Chaperones. *Curr. Top. Med. Chem.* 2016, 16(25), 2812-28.

Shrestha, L.; Patel, H. J.; Chiosis, G., Chemical tools to investigate mechanisms associated with HSP90 and HSP70 in disease. *Cell Chem. Biol.* 2016, 23(1), 158-172.

Patel, H. J.; Patel, P. D.; Ochiana, S. O.; Yan, P.; Sun, W.; Patel, M. R.; Shah, S. K.; Tramentozzi, E.; Brooks, J.; Bolaender, A.; Shrestha, L.; Stephani, R.; Finotti, P.; Leifer, C.; Li, Z.; Gewirth, D. T.; Taldone, T.; Chiosis, G., Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum hsp90 paralog grp94. *J Med. Chem.* 2015, 58 (9), 3922-43.

Rodina, A.; Taldone, T.; Kang, Y. L.; Patel, P. D.; Koren, J.; Yan, P. R.; Gomes, E. M. D.; Yang, C. H.; Patel, M. R.; Shrestha, L.; Ochiana, S. O.; Santarossa, C.; Maharaj, R.; Gozman, A.; Cox, M. B.; Erdjument-Bromage, H.; Hendrickson, R. C.; Cerchietti, L.; Melnick, A.; Guzman, M. L.; Chiosis, G., Affinity Purification Probes of Potential Use To Investigate the Endogenous Hsp70 Interactome in Cancer. *ACS Chem. Biol.* 2014, 9 (8), 1698-1705.

Hahne, K.; Vervacke, J. S.; Shrestha, L.; Donelson, J. L.; Gibbs, R. A.; Distefano, M. D.; Hrycyna, C. A., Evaluation of substrate and inhibitor binding to yeast and human isoprenylcysteine carboxyl methyltransferases (lcmts) using biotinylated benzophenone-containing photoaffinity probes. *Biochem. Bioph. Res. Commun.* 2012, 423 (1), 98-103.

Majmudar, J. D.; Hodges-Loaiza, H. B.; Hahne, K.; Donelson, J. L.; Song, J.; Shrestha, L.; Harrison, M. L.; Hrycyna, C. A.; Gibbs, R. A., Amide-modified prenylcysteine based lcmt inhibitors: Structure-activity relationships, kinetic analysis and cellular characterization. *Bioorg. Med. Chem.* 2012, 20 (1), 283-295.

Liza Shrestha 4/5

Communication preferences

Cookie preferences

Legal disclaimer

Accessibility Statement

Privacy policy

Public notices

© 2024 Memorial Sloan Kettering Cancer Center

Liza Shrestha 5/5